Salute e Benessere

Sai Life Sciences sets up Peptide Research Center in India

HYDERABAD, India, April03, 2025(GLOBE NEWSWIRE) -- Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), an innovator-focusedContract Research, Development, and Manufacturing Organization (CRDMO), has inaugurated a dedicated Peptide Research Center at its integrated R&D Campus in Hyderabad, India. Announcing the launch,Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said: “As the pharmaceutical industry evolves from small molecules to emerging...
Nasdaq GlobeNewswire
03/04/2025

ZINZINO AB (PUBL.): PRELIMINARY SALES REPORT Q1 2025

The group revenue increased with 60 % for Q1 2025 compared with the first quarter last year and amounted to SEK 725.9 (454.5) million. The group revenue increased with 60 % for Q1 2025 compared with the first quarter last year and amounted toSEK 725.9(454.5) million. Revenues were distributed as follows: Countries in regions:-The Nordics:Denmark, Faroe Island,Finland,Iceland,Norway,Sweden- Central Europe :Austria,Germany,Switzerland- East Europe :...
PR Newswire
03/04/2025

Kanazawa University research: Decoding how cells communicate by high-speed…

In this study, led by Keesiang Lim and Richard W. Wong, the team utilized HS-AFM to visualize the nanotopology of sEVs derived from HEK293T cells under physiological conditions. Their findings revealed distinct sEV subpopulations enriched with specific exosome markers, such as CD63 and CD81. Notably, they observed that sEVs smaller than 100 nm exhibited greater membrane rigidity and higher co-localization with exosomal markers compared to larger vesicles, which showed significant height…
PR Newswire
03/04/2025

Kanazawa University research: New Breakthrough in Cancer Treatment: Tiny…

Background Background Many modern cancer treatments, such as immune checkpoint inhibitors and cytokine therapies, help the immune system fight cancer. However, these treatments can sometimes harm healthy tissues and cause severe side effects. Extracellular vesicles (EVs) are tiny, bubble-like structures naturally produced by cells to communicate with each other. Scientists have recently explored their potential as a targeted drug delivery system. In this study, researchers successfully...
PR Newswire
03/04/2025

Boehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE…

CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company's aim of transforming the lives of people with cancer . Boehringer Ingelheim strengthens footprintin Swiss biotech innovation hub . Basel, Switzerland, Thursday, 03 .04.2025 – Today NBETherapeutics (NBE)a wholly owned subsidiary of Boehringer...
Nasdaq GlobeNewswire
03/04/2025

Kanazawa University research: Live imaging captures DNA folding in sperm cells…

In most cells, DNA is wrapped around proteins called histones, allowing it to be loosely packed and accessible for gene activity. However, in sperm cells, histones are replaced by protamines, which enable extreme DNA condensation. This compaction is essential for protecting genetic material during fertilization, ensuring efficient transport of DNA to the egg, and contributing to fertility and embryo development. Despite its importance, the precise steps of how protamines condense DNA into highly…
PR Newswire
03/04/2025

IRBM Expands Functional Genomics Platform to Strengthen Early Drug Discovery

To further enhance target validation, IRBM is expanding its genome editing toolkit with CRISPR tiling to systematically map functional domains within coding and regulatory regions, along with base and prime editing to introduce precise nucleotide modifications. These next-generation approaches—combined with the platform's high-throughput CRISPR screening, including stem cell engineering—are instrumental in building robust disease models and improving the reliability of target validation. To...
PR Newswire
03/04/2025

Novo Nordisk announces changes in Executive Management

Bagsværd, Denmark, 3 April 2025– Novo Nordisk today announced the following changes in Executive Management.After a distinguished career of 28 years with Novo Nordisk, hereof seven years as executive vice president of Commercial Strategy & Corporate Affairs, Camilla Sylvest has decided to leave the company. Consequently, as of 3 April 2025, the following organisational changes are implemented:Ludovic Helfgott, executive vice president, Rare Disease, will assume the responsibility...
Nasdaq GlobeNewswire
03/04/2025

LIfT BioSciences gains access to half a million allogeneic donors through…

Press release LIfT BioSciences gains access to half a million allogeneic donors through collaboration with Gift of Life BiologicsAccess to extensive donor pool supports LIfT's move into the clinic London,03 April 2025 – LIfT BioSciences, ('LIfT' or 'the Company'), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, and Gift of Life Biologics, ('GOLB') a leader in the provision of cellular starting material for cell therapies, announce a collaboration...
Nasdaq GlobeNewswire
03/04/2025

Pharming Group announces the filing of its 2024 Annual Report and Form 20-F

Leiden, the Netherlands, April 3, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the filing of its Annual Report for the year ended December 31, 2024 (the “Period”). The Annual Report is available under Investors/Financial documents on the Pharming.com website. The Company also announces the filing of its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC) for the Period. The 2024 Annual Report on...
Nasdaq GlobeNewswire
03/04/2025

Press Release: Rilzabrutinib granted orphan drug designation in the US for two…

Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicinesDesignation granted for warm autoimmune hemolytic anemia and IgG4-related diseaseRilzabrutinib is currently under regulatory review in the US, EU and China for potential use in immune thrombocytopenia Paris, April 3, 2025. The US Food and Drug Administration (FDA) has granted orphan drug designation to rilzabrutinib, an investigational, novel, advanced, oral, reversible Bruton's...
Nasdaq GlobeNewswire
03/04/2025

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first…

Ad hoc announcement pursuant to Art. 53 LR Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation Strategy) program 1Phase III data showed Vanrafia achieved proteinuria reduction of 36.1% (P<0.0001) vs. placebo with improvements seen at Week 6 and sustained through Week 36 and favorable safety 1,2 IgAN is a progressive, rare kidney disease; up to 50% of patients with...
Nasdaq GlobeNewswire
03/04/2025

NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

Global development program for JNJ-1900 (NBTXR3) proceeding as planned, with opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lung cancerDisciplined financial strategy toward long-term sustainability and growth continues to strengthen financial position through focused allocation of capital, the receipt of a planned milestone payment, the transfer of sponsorship for NANORAY-312, and an amendment to the global licensing...
Nasdaq GlobeNewswire
02/04/2025

Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference

Alkermes Contact: Jamie ConstantineInvestor Relations+1 781 873 2402 Alkermes Contact: Jamie ConstantineInvestor Relations +1 781 873 2402 Logo -https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg View original content: https://www.prnewswire.co.uk/news-releases/alkermes-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference-302418956.html
PR Newswire
02/04/2025

LBB Specialties Partners with Kerry Group to Launch Pharmaceutical Lactose to…

"Our partnership with Kerry expands our customers' access to high-quality pharmaceutical lactose ingredients. Kerry's long-standing technical expertise and commitment to product consistency provide formulators with reliable, high-performance solutions tailored to their specific needs. Together, we are redefining quality and innovation in pharmaceutical formulation," said Seth Burns, SVP of Life Sciences at LBB Specialties. "Our partnership with Kerry expands our customers' access…
PR Newswire
02/04/2025

EssilorLuxottica: EssilorLuxottica's employee shareholding plans reach record…

EssilorLuxottica's employee shareholding plans reach record investment, reflecting strong confidence in the Group's strategyToday, the Group totals almost 100,000 internal shareholders in 85 countriesParis, France (2 April 2025)– EssilorLuxottica continues to grow and create value for shareholders. Following record-breaking investments in the SuperBoost 2025 international shareholding plan and the French PEE in 2024, internal shareholders now total 97,000 across 85 countries, up...
Nasdaq GlobeNewswire
02/04/2025

Roche provides update on Phase III OCREVUS high dose study in people with…

MUSETTE trial was designed to determine whether a higher dose of the currently approved OCREVUS IV 600 mg would provide additional benefit to people living with relapsing multiple sclerosisThe trial did not meet its primary endpoint; results support OCREVUS IV 600 mg as the optimal dose to slow disability progression High dose was well tolerated with an overall comparable safety profile to OCREVUS IV 600 mg and no new safety signals observedThese data further support the efficacy...
Nasdaq GlobeNewswire
02/04/2025

FDA Watch: The Quiet Gold Rush in AI-Powered Medical Devices

VANCOUVER, BC, April 2, 2025 /PRNewswire/ -- Equity Insider News Commentary – Artificial Intelligence (AI) is quickly becoming a major force in healthcare, as use of AI applications in medical fields is growing rapidly. Researchers at Dartmouthrecently conducted the first clinical trial of a therapy chatbot powered by generative AI (genAI), and found that it resulted in significant improvements in participants' symptoms. Cleveland Clinic and UAE-based G42 recently started collaborating on the…
PR Newswire
02/04/2025

US Clinical Trial Services Market worth US$39.61 billion by 2030 with 9.2% CAGR…

Browse in-depth TOC on "US Clinical Trial Services Market" Browse in-depth TOC on "US Clinical Trial Services Market" 163 - Tables 62 – Figures 220 – Pages The small molecules segment accounted for the largest share of the US clinical trial services market by modality during the forecast period. Based on modality, the US clinical trial services market is divided into small molecules, biologics, and medical devices. The small molecule segment holds a dominant share of...
PR Newswire
02/04/2025

Traditional Wound Care Market worth US$9.12 billion by 2030 with 4.2% CAGR |…

Browse in-depth TOC on "Traditional Wound Care Market" Browse in-depth TOC on "Traditional Wound Care Market" 401 - Tables 50 - Figures 372 - Pages By Based on application,the traditional wound care market is divided into chronic wounds and acute wounds. Among these, acute wounds hold the largest market share in 2024 due to their increased numbers of road accidents, as well as rise in related injuries. The acute wound care market has 2 segments surgical & traumatic...
PR Newswire
02/04/2025

Baby Products Market Surges to USD 119.62 Billion by 2033, Propelled by 4.5%…

E-commerce penetration has revolutionized product accessibility, allowing brands to reach a wider consumer base with personalized offerings. Stringent safety regulations and compliance requirements across multiple regions present operational challenges for manufacturers. Supply chain disruptions and fluctuating raw material costs are impacting profitability. Competition is intensifying with private-label brands offering cost-effective alternatives to established players. Sustainable packaging…
PR Newswire
02/04/2025

NCCN 2025 Annual Conference Illustrates the Critical Impact of Cancer Research…

"We are proud to honor our founders' vision of sharing evidence-based, expert consensus-driven recommendations through clinical practice guidelines to improve cancer care," said Crystal S. Denlinger, MD, Chief Executive Officer, NCCN. "Over the years our organization has responded to a rapidly accelerating pace of discovery with record numbers of updates to our guidelines. Our work spans the spectrum from prevention and risk reduction through post-treatment survivorship and…
PR Newswire
02/04/2025

"miraDry Releases the First Ever Sweat Scope Report, Shedding Light on Underarm…

The study reveals that up to an astonishing 70% of women experience an increase in underarm sweat and odor as they approach menopause, with many using three or more coping strategies daily. The data also highlights the substantial impact on women's social lives and self-esteem, with a majority expressing heightened self-consciousness in social and professional settings. The study reveals that up to an astonishing 70% of women experience an increase in underarm sweat and odor as they approach...
PR Newswire
02/04/2025

Zero Candida Technologies Reports Full Year 2024 Financial Results and Business…

Business Highlights Business Highlights The following summarizes key business developments from the twelve months endedDecember 31, 2024, to the date of this release: Financial Results For the year endedDecember 31, 2024, Zero Candida Technologies Inc. reported research and development expenses ofCAD 1,276 thousand, compared toCAD 1,868 thousandin 2023, and general and administrative expenses ofCAD 965 thousand, compared toCAD 649 thousandin 2023. The...
PR Newswire
02/04/2025
Altri  Comunicati